(Q38005634)

26 August 2017

1 reference

title

The MPTP story: MAO activates tetrahydropyridine derivatives to toxins causing parkinsonism (English)

1 reference

26 August 2017

1 reference

Maret G

1

1 reference

26 August 2017

Testa B

2

1 reference

26 August 2017

Jenner P

3

1 reference

26 August 2017

el Tayar N

4

1 reference

26 August 2017

Carrupt PA

5

1 reference

26 August 2017

language of work or name

English

0 references

publication date

1 January 1990

1 reference

26 August 2017

Drug Metabolism Reviews

1 reference

26 August 2017

22

1 reference

26 August 2017

291-332

1 reference

26 August 2017

4

1 reference

The brain-stem lesions in Parkinsonism

26 August 2017

1 reference

https://api.crossref.org/works/10.3109%2F03602539009041087

Distribution of noradrenaline and dopamine (3-hydroxytyramine) in the human brain and their behavior in diseases of the extrapyramidal system

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602539009041087

Clues to the mechanism underlying dopamine cell death in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602539009041087

Aetiology of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602539009041087

Twin study of Parkinson disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602539009041087

The role of environmental toxins in the etiology of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602539009041087

Ecogenetics of Parkinson's disease: 4-hydroxylation of debrisoquine

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602539009041087

Presence of tetrahydroisoquinoline and 1-methyl-tetrahydro-isoquinoline in foods: Compounds related to Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602539009041087

Epidemiologic studies of Parkinson's disease. I. Smoking and Parkinson's disease: a survey and explanatory hypothesis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602539009041087

Parkinson's disease: a disorder due to nigral glutathione deficiency?

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602539009041087

Idiopathic Parkinson's disease, progressive supranuclear palsy and glutathione metabolism in the substantia nigra of patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602539009041087

Does levodopa aggravate Parkinson's disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602539009041087

Chronic parkinsonism secondary to intravenous injection of meperidine analogues

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602539009041087

Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602539009041087

A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602539009041087

Selective nigral toxicity after systemic administration of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyrine (MPTP) in the squirrel monkey

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602539009041087

Locus ceruleus lesions and eosinophilic inclusions in MPTP-treated monkeys.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602539009041087

The neurotoxin MPTP does not reproduce in the rhesus monkey the interregional pattern of striatal dopamine loss typical of human idiopathic Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602539009041087

Intraneuronal generation of a pyridinium metabolite may cause drug-induced parkinsonism.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602539009041087

1-Methyl-4-phenylpyridinium ion (MPP+): Identification of a metabolite of MPTP, a toxin selective to the substantia nigra

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602539009041087

Protection against the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine by monoamine oxidase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602539009041087

Metabolism of the neurotoxic tertiary amine, MPTP, by brain monoamine oxidase.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602539009041087

Role for monoamine oxidase-A (MAO-A) in the bioactivation and nigrostriatal dopaminergic neurotoxicity of the MPTP analog, 2'Me-MPTP.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602539009041087

Importance of monoamine oxidase A in the bioactivation of neurotoxic analogs of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602539009041087

Parkinsonism-inducing neurotoxin, N-methyl-4-phenyl-1,2,3,6 -tetrahydropyridine: uptake of the metabolite N-methyl-4-phenylpyridine by dopamine neurons explains selective toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602539009041087

Active uptake of MPP+, a metabolite of MPTP, by brain synaptosomes.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602539009041087

Uptake of N-methyl-4-phenylpyridinium ion (MPP(+)) into PC12h pheochromocytoma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602539009041087

Selectivity of the parkinsonian neurotoxin MPTP: toxic metabolite MPP+ binds to neuromelanin.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602539009041087

Characterization of the binding of N-methyl-4-phenylpyridine, the toxic metabolite of the parkinsonian neurotoxin N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, to neuromelanin

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602539009041087

The effect of platelet activating factor on pulmonary beta-adrenoceptors

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602539009041087

The catecholamine uptake blocker nomifensine protects against MPTP-induced parkinsonism in monkeys.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602539009041087

Energy-driven uptake of N-methyl-4-phenylpyridine by brain mitochondria mediates the neurotoxicity of MPTP.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602539009041087

Inhibition of NADH-linked oxidation in brain mitochondria by 1-methyl-4-phenyl-pyridine, a metabolite of the neurotoxin, 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602539009041087

Studies on the neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: inhibition of NAD-linked substrate oxidation by its metabolite, 1-methyl-4-phenylpyridinium.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602539009041087

Inhibition of mitochondrial NADH dehydrogenase by pyridine derivatives and its possible relation to experimental and idiopathic parkinsonism

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602539009041087

The inhibition site of MPP+, the neurotoxic bioactivation product of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine is near the Q-binding site of NADH dehydrogenase

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602539009041087

Inhibition of ATP synthesis by 1-methyl-4-phenylpyridinium ion (MPP+) in isolated mitochondria from mouse brains.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602539009041087

1-Methyl-4-phenylpyridinium (MPP+) increases oxidation of cytochrome-b in rat striatal slices.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602539009041087

Mechanism of the neurotoxicity of 1-methyl-4-phenylpyridinium (MPP+), the toxic bioactivation product of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602539009041087

Increased efflux rather than oxidation is the mechanism of glutathione depletion by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602539009041087

Potential bioactivation pathways for the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602539009041087

Studies on the 1-methyl-4-phenyl-2,3-dihydropyridinium species 2,3-MPDP+, the monoamine oxidase catalyzed oxidation product of the nigrostriatal toxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602539009041087

Bioactivation of MPTP: reactive metabolites and possible biochemical sequelae

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602539009041087

Chemically induced Parkinson's disease. II: Intermediates in the oxidation and reduction reactions of the 1-methyl-4-phenyl-2,3-dihydropyridinium ion and its deprotonated form

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602539009041087

Predicting Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602539009041087

MPTP: a neurotoxin relevant to the pathophysiology of Parkinson's disease. The 1985 George C. Cotzias lecture

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602539009041087

Inhibition of rat brain monoamine oxidase by some analogues of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and 1-methyl-4-phenylpyridinium ion.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602539009041087

Role of N-methyltransferases in the neurotoxicity associated with the metabolites of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and other 4-substituted pyridines present in the environment.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602539009041087

Characterization of the neurotoxic potential of m-methoxy-MPTP and the use of its N-ethyl analogue as a means of avoiding exposure to a possible Parkinsonism-causing agent

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602539009041087

Persistent depletion of striatal dopamine and its metabolites in mice by TMMP, an analogue of MPTP.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602539009041087

The pharmacology of the parkinsonian syndrome producing neurotoxin MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) and structurally related compounds

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602539009041087

Effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and several of its analogues on the dopaminergic nigrostriatal pathway in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602539009041087

1-Methyl-4-(2'-methylphenyl)-1,2,3,6-tetrahydropyridine (2'-CH3-MPTP) is a more potent dopaminergic neurotoxin than MPTP in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602539009041087

1-Methyl-4-cyclohexyl-1,2,3,6-tetrahydropyridine (MCTP): an alicyclic MPTP-like neurotoxin

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602539009041087

Synthesis and toxicity toward nigrostriatal dopamine neurons of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) analogues.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602539009041087

Potent neurotoxic fluorinated 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine analogs as potential probes in models of Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602539009041087

Inhibition of the tyrosine hydroxylase system by MPTP, 1-methyl-4-phenylpyridinium ion (MPP+) and the structurally related compounds in vitro and in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602539009041087

An endogenous substance of the brain, tetrahydroisoquinoline, produces parkinsonism in primates with decreased dopamine, tyrosine hydroxylase and biopterin in the nigrostriatal regions.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602539009041087

Tetrahydroisoquinoline alkaloids: in vivo metabolites of L-dopa in man.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602539009041087

Beta-carboline analogues of N-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP): endogenous factors underlying idiopathic parkinsonism?

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602539009041087

Methyltetrahydro-beta-carbolines and Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602539009041087

MPTP, MPP+ and mitochondrial function

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602539009041087

Further explorations of unnatural alkaloids.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602539009041087

The importance of the ‘4–5’ double bond for neurotoxicity in primates of the pyridine derivative MPTP

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602539009041087

The toxic actions of MPTP and its metabolite MPP+ are not mimicked by analogues of MPTP lacking an N-methyl moiety.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602539009041087

Chemical oxidation of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and its in vivo metabolism in rat brain and liver

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602539009041087

Metabolic studies on the nigrostriatal toxin MPTP and its MAO B generated dihydropyridinium metabolite MPDP+.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602539009041087

MPTP, the neurotoxin inducing Parkinson's disease, is a potent competitive inhibitor of human and rat cytochrome P450 isozymes (P450bufI, P450db1) catalyzing debrisoquine 4-hydroxylation.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602539009041087

Depression of the hepatic cytochrome P-450 monooxygenase system by the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602539009041087

N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) affects locomotor activity without producing a nigrostriatal lesion in the rat

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602539009041087

Repeated administration of N-methyl-4-phenyl 1,2,5,6-tetrahydropyridine to rats is not toxic to striatal dopamine neurones.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602539009041087

Dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602539009041087

Effect of 1-methyl-4-phenyl-1,2,3,6 tetrahydropyridine (MPTP) on monoamine neurotransmitters in mouse brain & heart

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602539009041087

Production of a Parkinson-like syndrome in the cat with N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): behavior, histology, and biochemistry.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602539009041087

Effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in the dog: effect of pargyline pretreatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602539009041087

Differences in the metabolism of MPTP in the rodent and primate parallel differences in sensitivity to its neurotoxic effects.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602539009041087

Correlation of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity with blood-brain barrier monoamine oxidase activity

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602539009041087

The biodisposition of MPP+ in mouse brain

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602539009041087

Effect of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on age-related changes in dopamine turnover and transporter function in the mouse striatum.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602539009041087

Aged mice are more sensitive to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine treatment than young adults.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602539009041087

Older dopaminergic neurons do not recover from the effects of MPTP.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602539009041087

Sites of the neurotoxic action of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in the macaque monkey include the ventral tegmental area and the locus coeruleus.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602539009041087

Subcellular compartmentalization of 1-methyl-4-phenylpyridinium with catecholamines in adrenal medullary chromaffin vesicles may explain the lack of toxicity to adrenal chromaffin cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602539009041087

Comparative molecular field analysis (CoMFA). 1. Effect of shape on binding of steroids to carrier proteins.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602539009041087

Interactions of monoamine oxidase with substrates and inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602539009041087

Tetrahydronorharmane (tetrahydro-beta-carboline), a physiologically occurring compound of indole metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602539009041087

Ethanol induces an increase of harman in the brain and urine of rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602539009041087

Formation of a beta-carboline (1,2,3,4-tetrahydro-1-methyl-beta-carboline-1-carboxylic acid) following intracerebroventricular injection of tryptamine and pyruvic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602539009041087

Formation of 1-methyl-?-carbolines in rats from their possible carboxylic acid precursor

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602539009041087

Paraquat and two endogenous analogues of the neurotoxic substance N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine do not damage dopaminergic nigrostriatal neurons in the mouse.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602539009041087

In vivo dopaminergic neurotoxicity of the 2-beta-methylcarbolinium ion, a potential endogenous MPP+ analog

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602539009041087

Endogenously formed norharman (beta-carboline) in platelet rich plasma obtained from porphyric rats

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602539009041087

Tetrahydroisoquinoline and 1-methyl-tetrahydroisoquinoline as novel endogenous amines in rat brain.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602539009041087

The route and significance of endogenous synthesis of alkaloids in animals

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602539009041087

Tetrahydroisoquinoline lacks dopaminergic nigrostriatal neurotoxicity in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602539009041087

Inhibition of mitochondrial NADH-ubiquinone oxidoreductase activity and ATP synthesis by tetrahydroisoquinoline.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602539009041087

The sensitivity of nigrostriatal dopamine neurons to MPP+ does not increase with age.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602539009041087

10.3109/03602539009041087

21 January 2018

Identifiers

DOI

1 reference

26 August 2017

1 reference